NF-κB and cell-cycle regulation: The cyclin connection

Cytokine and Growth Factor Reviews

Volumn 12, Issue 1, 2001, Pages 73-90

  Joyce, David ^a   Albanese, Chris ^b   Steer, Jay ^a   Fu, Maofu ^b   Bouzahzah, Boumediene ^b   Pestell, Richard G ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclin dependent kinases; Cyclins; I B kinase (IKK) complex; NF B

Indexed keywords

BCR ABL PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; GROWTH FACTOR; HORMONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGENIC AGENT; PROTEIN C REL; PROTEIN P105; PROTEIN P50; RAC PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR; PROTEIN P16INK4A;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELLULAR DISTRIBUTION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME SUBUNIT; HUMAN; HUMAN CELL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; ANIMAL; CELL DIVISION; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; ONCOGENE; PHYSIOLOGY;

AVES; MAMMALIA;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMANS; MITOGENS; NF-KAPPA B; ONCOGENES;

EID: 0034744949     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(00)00018-6     Document Type: Review

References (222)

1. NF-kappa B: Ten years after
2. NF-kappa B and Re1 proteins: Evolutionarily conserved mediators of immune responses
3. A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site
4. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the re1 oncogene product
5. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50
6. DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a re1-related polypeptide
7. Isolation of a re1-related human cDNA that potentially encodes the 65-κD subunit of NF-kappa B
8. Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65
9. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA
10. Re1/NF-kappa B/I kappa B family: Intimate tales of association and dissociation
11. Differential interactions of Re1-NF-kappa B complexes with I kappa B alpha determine pools of constitutive and inducible NF-kappa B activity
12. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300
13. Re1A/p65 is a molecular target for the immunosuppressive action of protein kinase A
14. Transcriptional activation by NF-kappaB requires multiple coactivators
15. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: A mechanism for cytoplasmic retention
16. I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: A new member of the I kappa B family
17. The NF-kappa B p50 precursor, p105, contains an internal I kappa B-like inhibitor that preferentially inhibits p50
18. A new member of the I kappaB protein family, I kappaB epsilon, inhibits Re1A (p65)-mediated NF-kappaB transcription
19. I kappa B epsilon, a novel member of the I kappa B family, controls Re1A and cRe1 NF-kappa B activity
20. NF-kappa B subunit-specific regulation of the interleukin-8 promoter
21. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition
22. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites
23. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner
24. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins
25. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B
26. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers
27. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-kappa B subunit
28. NF-κB: A lesson in family values
29. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction
30. Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages
31. Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium
32. Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB
33. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB
34. Induction of NF-kappa B-like activity by platelet-derived growth factor in mouse fibroblasts
35. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation
36. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB
37. Identification and characterization of an IkappaB kinase
38. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation
39. p105 and p98 precursor proteins play an active role in NF-kappa B-mediated signal transduction
40. Mechanistic aspects of NF-kappa B regulation: The emerging role of phosphorylation and proteolysis
41. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B
42. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation
43. Structure of an IkappaBalpha/NF-kappaB complex
44. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex
45. Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis
46. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex
47. Regulation of the NF-kappaB activation pathway by isolated domains of FIP3/ IKKgamma, a component of the IkappaB-alpha kinase complex
48. Recruitment of the IK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKK) upon receptor stimulation
49. Bridging the gap: Composition, regulation, and physiological function of the IkappaB kinase complex
50. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation
51. The IκB kinase (IKK) and NF-κB: Key elements of proinflammatory signalling
52. IKKε is part of a novel PMA-inducible IκB kinase complex
53. Regulation of Re1A subcellular localization by a putative nuclear export signal and p50
54. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1
55. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176
56. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK
57. HTLV-I Tax protein binds to MEKK1 to stimulate IκB kinase activity and NF-κB activation
58. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1
59. MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta
60. Activation of the IκB kinase complex by MEKK1, a kinase of the JNK pathway
61. IκB Kinase (IKK) regulation of IKK kinase activity
62. The kinase TAK1 can activate the NIK-I kappaB, as well as the MAP kinase cascade in the IL-1 signalling pathway
63. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta
64. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases
65. IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein
66. Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma
67. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase
68. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation
69. Integration of Rac-dependent regulation of cyclin D1 transcription through an NF-κB-dependent pathway
70. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases
71. Zeta PKC induces phosphorylation and inactivation of I kappa B-alpha in vitro
72. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B
73. Sphingomyelinase activates proteolytic I kappa B-alpha degradation in a cell-free system
74. Hydrogen peroxide as a potent activator of T lymphocyte functions
75. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1
76. Effects of oxidants and antioxidants on nuclear factor kappa B activation in three different cell lines: Evidence against a universal hypothesis involving oxygen radicals
77. Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes
78. A new rac target POSH containing scaffold protein involved in the JNK and NF-κB signalling pathways
79. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor
80. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation
81. Control of IκB proteolysis by site-specific, signal-induced phosphorylation
82. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli
83. Identification of the receptor component of the IκB-ubiquitin ligase
84. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skpl and HOS to catalyze the ubiquitination of IκBα
85. The SCF-βTRCP ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBβ and β-catenin and stimulates IκBα ubiquitination in vitro
86. Signal-induced ubiquitination of IκBα by the F-box protein, Slimb/β-TrCP
87. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway
88. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity
89. CREB-binding protein/p300 are transcriptional coactivators of p65
90. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator
91. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation
92. Cancer cell cycles
93. The retinoblastoma protein and cell cycle control
94. Identification of the cyclin D1 gene as a target of ATF-2 in chondrocytes
95. Fos family members induce cell cycle entry by activating cyclinD1
96. Cyclin D1 is a nuclear protein required for cell cycle progression in G1
97. Cyclin D1 is required for S-phase traversal in bovine tracheal myocytes
98. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin dependent kinase-pRb-controlled G1 checkpoint
99. Cyclin D1 is dispensible for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity
100. Cyclin D and oncogenesis
101. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts
102. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
103. NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition
104. NF-κB controls cell growth and differentiation through the transcriptional regulation of cyclin D1
105. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Spl
106. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway
107. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
108. The cyclin D1 gene is a target of the β-catenin/ LEF-1 pathway
109. β-catenin regulates expression of cyclin D1 in colon carcinoma cells
110. Transcriptional regulation of cyclin D1 promoter by STAT5: Its involvement in cytokine-dependent growth of hematopoietic cells
111. Stat3 as an oncogene
112. D-src signaling in breast cancer cells
113. Induction of cyclin D1 by simian virus 40 small tumor antigen
114. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
115. Cloning of a D-type cyclin from murine erythroleukemia cells
116. Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation
117. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation
118. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E
119. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system
120. Cyclin E-induced S phase without activation of the pRb/E2F pathway
121. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system
122. Differential regulation of E2F trans-activation by cyclin/cdk2 complexes
123. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase
124. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint
125. How proteolysis drives the cell cycle
126. Mitosis in transition
127. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
128. ARF
129. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
130. New functional activities for the p21 family of CDK inhibitors
131. Assembly of cyclin D-dependent kinase and titration of p27Kipl regulated by mitogen-activated protein kinase kinase (MEK1)
132. ARF, participates in a regulatory feedback loop with p53 and MDM2
133. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
134. WAF1, a potential mediator of p53 tumor suppression
135. The p21 Cdk-interacting protein Cipl is a potent inhibitor of the cyclin D-dependent kinases
136. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
137. p27, a novel inhibitor of G1 cyclin-protein kinase activity, is related to p21
138. p57KIP2, a structurally distinct member of the p21CIPI Cdk inhibitor family, is a candidate tumor suppressor gene
139. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
140. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2
141. CIPI/WAFI undergo normal development, but are defective in G1 checkpoint control
142. p21-containing cyclin kinases exist in both active and inactive states
143. Inhibition of cyclin-dependent kinases by p21
144. Cdk-interacting protein I directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme
145. Kip1-deficient mice
146. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
147. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
148. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β
149. Formation of p27-CDK complexes during the human mitotic cell cycle
150. Kip2 results in increased apoptosis and delayed differentiation during mouse development
151. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome
152. Increased and altered DNA binding of p53 by S and G2/M but not G1 cyclin-dependent kinases
153. B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation
154. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-Related transcription factors
155. CDK-independent activation of estrogen receptor by cyclin DI
156. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4
157. The retinoblastoma protein: More than a tumor suppressor
158. The retinoblastoma tumor suppressor protein
159. Recruitment of p300/CBP in p53-dependent signal pathways
160. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb
161. DRTFI/E2F: An expanding family of heterodimeric transcription factors implicated in cell-cycle control
162. E2F and the molecular mechanisms of early cell-cycle control
163. Introduction to the E2F family: Protein structure and gene regulation
164. Induction of NF-κB DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts
165. Cytokine induction of nuclear factor kappa B in cycling and growth-arrested cells. Evidence for cell cycle-independent activation
166. Rapid DNA binding by nuclear factor kappa B in hepatocytes at the start of liver regeneration
167. Rapid activation of post-hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver
168. Inhibition of NF-kappaB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis
169. Role of Re1/NF-kappaB transcription factors during the outgrowth of the vertebrate limb
170. NF-kappa B is induced in the nuclei of cultured rat aortic smooth muscle cells by stimulation of various growth factors
171. Mice lacking the c-Re1 proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression
172. Embryonic lethality and liver degeneration in mice lacking the Re1A component of NF-kappa B
173. NF-kappa B Re1A-deficient lymphocytes: Normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses
174. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses
175. B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching
176. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2
177. The P65 subunit of NF-kappa B is redundant with p50 during B cell proliferative responses, and is required for germline CH transcription and class switching to IgG3
178. Absence of tumor necrosis factor rescues Re1A-deficient mice from embryonic lethality
179. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death
180. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
181. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
182. Suppression of TNF-alpha-induced apoptosis by NF-kappaB
183. Inhibition of NF-kappaB/Re1 induces apoptosis of murine B cells
184. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras
185. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMPI domain important for B-lymphocyte transformation: Role in NF-kappaB activation
186. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B
187. Control of cell cycle entry and apoptosis in B lymph ocytes infected by Epstein-Barr virus
188. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB
189. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase
190. Limb and skin abnormalities in mice lacking IKKα
191. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene
192. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice
193. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis
194. Severe liver degeneration and lack of NF-κB activation in NEMO/IKK-deficient mice
195. Female mice heterozygous for IKK/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti
196. NEMO/IKK-deficient mice model incontinentia pigmenti
197. Genomic rearrangment in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti (IP)
198. Re1/NF-kappaB/IkappaB proteins and cancer
199. Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies
200. Rearranged NFκB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators
201. Highly-expressed p100/p52 (NFκB2) sequesters other NF-κB-Related proteins in the cytoplasm of human breast cancer cells
202. Aberrant nuclear factor-κB/Re1 expression and the pathogenesis of breast cancer
203. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth
204. Selective activation of NF-κB subunits in human breast cancer: Potential roles for NF-κB2/p52 and for Bcl-3
205. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH3T3 cells
206. Reduced skin tumor development in cyclin Dl-deficient mice highlights the oncogenic ras pathway in vivo
207. 2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun
208. Rac regulation of transformation, gene expression and actin organisation by multiple, PAK-independent pathways
209. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
210. Multiple control levels of cell proliferation by human T-cell leukemia virus type I Tax protein
211. Molecular interactions between HTLV-1 Tax protein and the NF-kappa B/kappa B transcription complex
212. Inducible regulatory elements in the human cyclin D1 promoter
213. Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function
214. Glucocorticoids suppress TNF-α expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-κB and c-Jun/ATF-2 binding sites in the promoter
215. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase
216. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic helix-loop-helix regulators
217. Cyclin mediated inhibition of muscle gene expression via a mechanism that is independent of pRB phosphorylation
218. Activation of the nuclear factor-κB by Rho, CDC42, and Rac-1 proteins
219. Repression of NF-kappaB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators
220. Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation
221. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1
222. Versatile molecular glue. Transcriptional control